Back to Agenda
Session 12: Co-track Grand Q&A Panel and Closing Remarks
Session Chair(s)
Ramesh Raghavachari, PhD
Supervisor, Unit 3/DPQA IV/OPQA I/OPQ/CDER, FDA, United States
Session 12: Co-track Grand Q&A Panel and Closing Remarks
Speaker(s)
Speaker
Nedim Emil Altaras, PhD
Senior Vice President, Technical Development, Moderna, United States
Panelists
Paul C. Brown, PhD
Associate Director for Pharmacology and Toxicology, OND, CDER, FDA, United States
Speaker
Daniel Capaldi, PhD
Vice President, Analytical and Process Development, Ionis Pharmaceuticals, Inc, United States
Speaker
Jeffrey Foy, PhD
Executive Director, Toxicology, Nimbus Therapeutics, United States
Panelist
Lois Freed, PhD
Director, Division of Pharmacology/Toxicology-Neuroscience (DPT-N), CDER, FDA, United States
Speaker
Laura Sepp-Lorenzino, PhD
Chief Scientific Officer, Intellia Therapeutics, Inc., United States
Panelist
Barry Ticho, MD, PhD
Chief Medical Officer, Stoke Therapeutics, United States
Have an account?